Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diva LaboratoriesROCO:4153 +0.62%76 EV-to-EBIT is 12.36 as of Sep. 05, 2026, which is 37% below its 10-year median of 19.61. GuruFocus rates ROCO:4153 with a GF Score™ of 76/100 and a GF Value™ of NT$38.61 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 108 Medical Diagnostics & Research companies, Diva Laboratories ranks better than 74.07% on this metric.
The historical rank and industry rank for Diva Laboratories's EV-to-EBIT or its related term are showing as below:
ROCO:4153'
s EV-to-EBIT Range Over the Past 10 Years
Min: -649.79 Med: 19.61 Max: 390.3
Current: 12.36
During the past 13 years, the highest EV-to-EBIT of Diva Laboratories was 390.30. The lowest was -649.79. And the median was 19.61.
ROCO:4153's EV-to-EBIT is ranked better than 74.07% of 108
companies
in the Medical Diagnostics & Research industry
Industry Median: 24.48
vs ROCO:4153: 12.36
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Diva Laboratories's Enterprise Value for the quarter that ended in Jun. 2026 was NT$1,212.5 Mil.
Diva Laboratories's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$110.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diva Laboratories EV-to-EBIT Related Terms
Diva Laboratories EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Diva Laboratories's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4153 vs TMO, DHR, NTRA: EV-to-EBIT Comparison
For the Diagnostics & Research subindustry, Diva Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diva Laboratories EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diva Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Diva Laboratories's EV-to-EBIT falls into.
Diva Laboratories's current Enterprise Value is NT$1,365.1 Mil.
Diva Laboratories's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$110.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diva Laboratories (ROCO:4153) has a EV-to-EBIT of 12.36 as of Sep. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Diva Laboratories and its competitors. This is 37% below median its historical median of 19.61. According to the industry distribution chart, Diva Laboratories ranks #28 out of 108 companies in the Medical Diagnostics & Research industry, placing it in the top 25.9%.
Is Diva Laboratories' EV-to-EBIT too high?
Diva Laboratories' current EV-to-EBIT of 12.36 is 37% below median its 10-year median of 19.61. The Medical Diagnostics & Research industry median EV-to-EBIT is 24.48. Diva Laboratories' value of 12.36 is 49.5% below this industry median. Based on the distribution chart, Diva Laboratories ranks #28 out of 108 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diva Laboratories has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diva Laboratories' EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diva Laboratories ranks #28 out of 108 companies for EV-to-EBIT. This puts Diva Laboratories in the upper half of its industry. The industry median EV-to-EBIT is 24.48. Diva Laboratories' value of 12.36 is 49.5% below this benchmark. While the company's 10-year median is 19.61 vs. the industry median of 24.48, Diva Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 24.48, based on 108 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diva Laboratories's current EV-to-EBIT of 12.36 is 49.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Diva Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 24.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diva Laboratories's current EV-to-EBIT is 12.36, which is 37% below median its own 10-year median of 19.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diva Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Diva Laboratories (ROCO:4153) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$38.61, compared to a current price of NT$32.60 — trading 15.6% below its estimated fair value. The current EV-to-EBIT is 12.36, which is 37% below median its 10-year median of 19.61 and 49.5% below the Medical Diagnostics & Research industry median of 24.48. Diva Laboratories' overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Diva Laboratories (ROCO:4153), the current EV-to-EBIT is 12.36 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diva Laboratories (ROCO:4153) Overvalued in 2026?
Based on GuruFocus' analysis, Diva Laboratories stock appears to be undervalued.
The current stock price of NT$32.60 is trading 15.6% below its estimated GF Value™ of NT$38.61.
GuruFocus considers Diva Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4153:
EV-to-EBIT: 12.36 (37% below median its 10-year median of 19.61)
GF Value™: NT$38.61 vs. price of NT$32.60 (15.6% below fair value)
Industry Position: 49.5% below the Medical Diagnostics & Research median (#28 of 108)
No single metric tells the full story. See the ROCO:4153 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diva Laboratories Ltd is engaged in the sale, manufacturing and development of medical equipment and computer-related devices. Its products are divided into Medical display which includes radiology, endo/surgical, touch, and embedded display; and Industrial display which includes touch display monitors. It derives revenue from sale of Medical monitors, Medical parts, Industrial monitors, Industrial parts, and Parts. Geographically it operates and derives revenue from Taiwan.
76GF Score
Get the complete analysis for ROCO:4153
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4153 has been successfully added to your 
